Bioact Mater. 2026 Jul 12;66:487-507(IF:23.6).
2026-07-12Bioact Mater. 2026 Jul 12;66:487-507.doi: 10.1016/j.bioactmat.2026.06.047. Targeting ROAM1 with UDP-GlcNAc nanosheets selective activates lysosomal AMPK to resolve metabolic dysfunction-associated steatotic liver disease. (IF:23.6).